Search results
Results From The WOW.Com Content Network
"The National Comprehensive Cancer Network (NCCN)". J Med Libr Assoc. 92 (3): 382– 3. PMC 442186. "New developments from National Comprehensive Cancer Network (NCCN) outlined recently" Physician Law Weekly August 1, 2007 "New Guidelines Updates from National Comprehensive Cancer Network" [dead link ] Cancerwatch Online (March 2004) 13(3)
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The National Comprehensive Cancer Network (NCCN) guidelines recommend bilateral prophylactic mastectomy and bilateral salpingo-oophorectomy for women who are carriers of germline BRCA1/2 mutation. At the age of 35 to 40 years, or once childbearing is completed, the procedure is recommended for risk reduction purposes.
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
Get 24x7 AOL Live expert help for all your AOL needs - from email to login, technical questions, mobile email, and more. Plus, you'll get security products to help protect your identity and data.
AOL Live Support Plus includes our top-of-the-line support and security products that will help protect your identity and information online. Get started today! Support when you need it: 24x7 Live Support gives you access to AOL experts over the phone or online chat, 24 hours a day, 7 days a week. Our experts are ready to assist you with any of ...
The American National Comprehensive Cancer Network's official guidelines list TTFields as an option for the treatment of recurrent glioblastoma, but note substantial disagreement among the members of the expert panel making this recommendation. [2] High-quality evidence for the efficacy of TTFields in oncology is limited.